News | May 29, 2024
IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
The new facility will be able to handle four times as many patients as the previous facility.
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
According to the National Institutes of Health, more than six million Americans, most age 65 or older, may have dementia caused by Alzheimer's disease, a brain disorder known to slowly destroy memory and thinking skills
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Subscribe To Our Newsletter & Stay Updated
